GG
HRTX icon

Gleason Group’s Heron Therapeutics HRTX Stock Holding History

Gleason Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,670
Closed -$8.4K – 217
2025
Q3 		$8.4K Hold
6,670
– – ﹤0.01% 162
2025
Q2 		$13.8K Hold
6,670
– – ﹤0.01% 162
2025
Q1 		$14.7K Hold
6,670
– – ﹤0.01% 154
2024
Q4 		$10.2K Hold
6,670
– – ﹤0.01% 166
2024
Q3 		$13.3K Hold
6,670
– – ﹤0.01% 157
2024
Q2 		$23.3K Hold
6,670
– – ﹤0.01% 154
2024
Q1 		$18.5K Hold
6,670
– – ﹤0.01% 149
2023
Q4 		$11.3K Buy
+6,670
New +$7.34K ﹤0.01% 175

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Gleason Group's HRTX Position: Q4 2025 in Review

Gleason Group sold out of Heron Therapeutics (HRTX) in Q4 2025, closing a stake of 6,670 shares — an estimated $8.4K sold.

Gleason Group first reported a position in HRTX in Q4 2023 and held it in 8 quarters. The position peaked at $23.3K in Q2 2024. 170 funds tracked by Wall St. Rank hold HRTX as of Q4 2025.

  • Gleason Group reported no remaining Heron Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Gleason Group sold 6,670 Heron Therapeutics shares in Q4 2025, an estimated $8.4K.
  • Gleason Group first reported a position in Heron Therapeutics in Q4 2023 and held it in 8 quarters.
  • Gleason Group's Heron Therapeutics position peaked at $23.3K in Q2 2024.
  • 170 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2025.

Based on Gleason Group's 13F filing for Q4 2025, filed 15 Jan 2026.